Eli Lilly and Company (NYSE:LLY - Free Report) - Analysts at Leerink Partnrs lowered their Q1 2025 earnings per share (EPS) estimates for Eli Lilly and Company in a research report issued to clients and investors on Monday, April 21st. Leerink Partnrs analyst D. Risinger now forecasts that the company will post earnings per share of $2.68 for the quarter, down from their previous forecast of $4.40. The consensus estimate for Eli Lilly and Company's current full-year earnings is $23.48 per share. Leerink Partnrs also issued estimates for Eli Lilly and Company's FY2025 earnings at $21.75 EPS.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%.
LLY has been the topic of a number of other research reports. Berenberg Bank set a $970.00 price target on shares of Eli Lilly and Company in a report on Thursday, January 16th. Guggenheim dropped their target price on Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating on the stock in a research report on Monday, April 14th. Morgan Stanley reduced their price objective on shares of Eli Lilly and Company from $1,146.00 to $1,124.00 and set an "overweight" rating for the company in a research note on Wednesday, April 9th. StockNews.com upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. Finally, Cantor Fitzgerald assumed coverage on shares of Eli Lilly and Company in a research note on Tuesday. They set an "overweight" rating and a $975.00 target price for the company. Two analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of "Moderate Buy" and a consensus price target of $1,017.00.
Read Our Latest Report on Eli Lilly and Company
Eli Lilly and Company Trading Up 0.4 %
Shares of NYSE:LLY opened at $830.57 on Thursday. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The firm has a market cap of $787.52 billion, a P/E ratio of 70.93, a P/E/G ratio of 1.40 and a beta of 0.51. The company has a 50 day moving average of $826.81 and a 200-day moving average of $819.07. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00.
Institutional Investors Weigh In On Eli Lilly and Company
Several hedge funds and other institutional investors have recently added to or reduced their stakes in LLY. Highline Wealth Partners LLC lifted its stake in Eli Lilly and Company by 80.0% in the 4th quarter. Highline Wealth Partners LLC now owns 45 shares of the company's stock valued at $35,000 after buying an additional 20 shares in the last quarter. Mascagni Wealth Management Inc. acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $43,000. FPC Investment Advisory Inc. raised its position in Eli Lilly and Company by 358.3% in the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock valued at $45,000 after purchasing an additional 43 shares during the period. Prudent Man Investment Management Inc. acquired a new position in Eli Lilly and Company in the fourth quarter valued at about $48,000. Finally, Compass Financial Services Inc purchased a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $50,000. 82.53% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling at Eli Lilly and Company
In other news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. This trade represents a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.13% of the company's stock.
About Eli Lilly and Company
(
Get Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
